Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell D Cohen

Showing results (71-80 of 142) with videos related to

Pageof 15
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2024
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's DiseaseAdar Zinger, David Choi, Natalie Choi, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?Bridget M Hron, Russell D Cohen, Scott J Johnson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 5, 2022
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary CenterNathaniel A Cohen, David Choi, Tenzin Choden, et al.
Inflammatory Bowel Diseases|April 2, 2011
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral centerRussell D Cohen, Jeffrey R Lewis, Hannah Turner, et al.
Inflammatory Bowel Diseases|February 23, 2013
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease centerAtsushi Sakuraba, Kian Keyashian, Chase Correia, et al.
Plos One|August 25, 2017
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel diseaseDejan Micic, John N Gaetano, Jonah N Rubin, et al.
Inflammatory Bowel Diseases|March 29, 2020
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel DiseaseParita Patel, Guimin Gao, George Gulotta, et al.
Digestive Diseases and Sciences|June 4, 2026
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel DiseaseNavneet Natt, David Choi, Asher Shafrir, et al.
Advances in Therapy|February 5, 2025
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature ReviewPiotr Wiland, Charlotte Both, Norman B Gaylis, et al.
Digestive Diseases (Basel, Switzerland)|December 8, 2021
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative ColitisMillie D Long, Russell D Cohen, Timothy W Smith, et al.
Pageof 15

Showing results (71-80 of 142) with videos related to

Sort By:
Pageof 15
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 26, 2024
Long-term Effectiveness and Safety of Risankizumab in Patients with Crohn's DiseaseAdar Zinger, David Choi, Natalie Choi, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: is unrealised adult height resulting from paediatric Crohn's disease associated with a potential reduction in lifetime earnings?Bridget M Hron, Russell D Cohen, Scott J Johnson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 5, 2022
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary CenterNathaniel A Cohen, David Choi, Tenzin Choden, et al.
Inflammatory Bowel Diseases|April 2, 2011
Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral centerRussell D Cohen, Jeffrey R Lewis, Hannah Turner, et al.
Inflammatory Bowel Diseases|February 23, 2013
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease centerAtsushi Sakuraba, Kian Keyashian, Chase Correia, et al.
Plos One|August 25, 2017
Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel diseaseDejan Micic, John N Gaetano, Jonah N Rubin, et al.
Inflammatory Bowel Diseases|March 29, 2020
Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel DiseaseParita Patel, Guimin Gao, George Gulotta, et al.
Digestive Diseases and Sciences|June 4, 2026
Combining Guselkumab with Upadacitinib Is Safe and Effective in the Treatment of Medically Complex Inflammatory Bowel DiseaseNavneet Natt, David Choi, Asher Shafrir, et al.
Advances in Therapy|February 5, 2025
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature ReviewPiotr Wiland, Charlotte Both, Norman B Gaylis, et al.
Digestive Diseases (Basel, Switzerland)|December 8, 2021
Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative ColitisMillie D Long, Russell D Cohen, Timothy W Smith, et al.
Pageof 15